| Clinical Trial Update III | PACE: Pacing to Avoid Cardiac Enlargement (PACE) study | Cheuk-Man Yu (Hong Kong SAR, CN) | Arrhythmias / Pacing / Resynchronisation | 01 Sep 2010 |
| Clinical Trial Update III | Discussant: PACE: Pacing to Avoid Cardiac Enlargement (PACE) study | William Abraham (US) | Arrhythmias / Pacing / Resynchronisation | 01 Sep 2010 |
| Clinical Trial Update III | CARE HF LTFU: Cardiac Resynchronisation in Heart Failure: Long-Term Follow-up | John Cleland (UK) | Arrhythmias / Pacing / Resynchronisation | 01 Sep 2010 |
| Clinical Trial Update III | Discussant: CARE HF LTFU: Cardiac Resynchronisation in Heart Failure: Long-Term Follow-up | Ole A Breithardt (DE) | Arrhythmias / Pacing / Resynchronisation | 01 Sep 2010 |
| Clinical Trial Update III | The REALISE-AF registry: an international, observational, cross-sectional survey describing characteristics, cardiovascular risk, and management of patients with atrial fibrillation | Philippe Gabriel Steg (FR) | Arrhythmias / Pacing / Resynchronisation | 01 Sep 2010 |
| Clinical Trial Update III | Discussant: The REALISE-AF registry: an international, observational, cross-sectional survey describing characteristics, cardiovascular risk, and management of patients with atrial fibrillation | Josep Brugada Terradellas (ES) | Arrhythmias / Pacing / Resynchronisation | 01 Sep 2010 |
| Treatment of atrial fibrillation in heart failure | Rate control: which drugs? | Harry Crijns (NL) | Heart failure / LV dysfunction | 01 Sep 2010 |
| Treatment of atrial fibrillation in heart failure | Pulmonary vein isolation: for which patients? | Philippe Mabo (FR) | Heart failure / LV dysfunction | 01 Sep 2010 |
| Treatment of atrial fibrillation in heart failure | Other electrical treatment. | Jean-Yves Le Heuzey (FR) | Heart failure / LV dysfunction | 01 Sep 2010 |
| Treatment of atrial fibrillation in heart failure | Prevention of stroke. | Harald Darius (DE) | Heart failure / LV dysfunction | 01 Sep 2010 |
| Clinical Trial Update III | KYOTO HEART: Effect of valsartan on cardiovascular outcomes in patients with high-risk hypertension: updated analyses of the KYOTO HEART Study | Hiroaki Matsubara (Japan) | Hypertension | 01 Sep 2010 |
| Clinical Trial Update III | Discussant: KYOTO HEART: Effect of valsartan on cardiovascular outcomes in patients with high-risk hypertension: updated analyses of the KYOTO HEART Study | Stephane Laurent (FR) | Hypertension | 01 Sep 2010 |
| Clinical Trial Update III | JIKEI HEART: Effect of valsartan in Japanese subjects with coronary heart disease: Sub-analysis of results of JIKEI HEART Study | Mitsuyuki Shimizu (Japan) | Hypertension | 01 Sep 2010 |
| Treatment of stable coronary disease | Prognosis and prevention. | Huon Gray (UK) | Interventional cardiology | 01 Sep 2010 |
| Treatment of stable coronary disease | Pharmacotherapy. | Jose Lopez-Sendon (ES) | Interventional cardiology | 01 Sep 2010 |
| Treatment of stable coronary disease | Percutaneous intervention. | Jean Marco (FR) | Interventional cardiology | 01 Sep 2010 |
| Treatment of stable coronary disease | Surgical revascularisation. | Paul Sergeant (BE) | Interventional cardiology | 01 Sep 2010 |
| Treatment of stable coronary disease | ... and the answer is ... | Michal Tendera (PL) | Interventional cardiology | 01 Sep 2010 |
| Clinical Trial Update III | TREAT: Trial to Reduce Cardiovascular Events with Aranesp (darbepoetin) Therapy | John McMurray (UK) | Ischaemia / ACS / infarction | 01 Sep 2010 |
| Clinical Trial Update III | Discussant: TREAT: Trial to Reduce Cardiovascular Events with Aranesp (darbepoetin) Therapy | Karl Swedberg (SE) | Ischaemia / ACS / infarction | 01 Sep 2010 |
| Highlight Session | Basic Science. | Axel Radlach Pries (DE) | NA | 01 Sep 2010 |
| Highlight Session | Hypertension. | Robert Fagard (BE) | NA | 01 Sep 2010 |
| Highlight Session | Imaging. | Frank Rademakers (BE) | NA | 01 Sep 2010 |
| Highlight Session | Interventional cardiology. | Carlo Di Mario (UK) | NA | 01 Sep 2010 |
| Highlight Session | Valvular heart disease. | Raphael Rosenhek (AT) | NA | 01 Sep 2010 |
| Highlight Session | Heart failure and cardiomyopathies. | Marco Metra (IT) | NA | 01 Sep 2010 |
| Highlight Session | Preventive cardiology. | David Allan Wood (UK) | NA | 01 Sep 2010 |
| Treatment of atrial fibrillation in heart failure | Rhythm control: which drugs? | Stefan H Hohnloser (DE) | Valvular disease | 01 Sep 2010 |
| Percutaneous coronary intervention in 3 vessel disease and main stem | Complex 3 vessel disease. | M.Ostojic ( Belgrade-Serbia) | Interventional cardiology | 28 Aug 2011 |
| Percutaneous coronary intervention in 3 vessel disease and main stem | Complex main stem lesion. | M C.Morice ( Massy-France) | Interventional cardiology | 28 Aug 2011 |
| Percutaneous coronary intervention in 3 vessel disease and main stem | What do the guidelines say? | D.Dudek ( Krakow-Poland) | Interventional cardiology | 28 Aug 2011 |
| Genetic determinants of cardiovascular disease: are genome-wide association studies the whole answer? | Genome-wide association studies: only a partial success story? | H.Watkins ( Oxford-United Kingdom) | Cardiovascular system (patho)physiology | 28 Aug 2011 |
| Genetic determinants of cardiovascular disease: are genome-wide association studies the whole answer? | Where to find the missing heritability? | F.Cambien ( Paris-France) | Cardiovascular system (patho)physiology | 28 Aug 2011 |
| Genetic determinants of cardiovascular disease: are genome-wide association studies the whole answer? | How to interpret sequence data. | D F.Gudbjartsson ( Reykjavik-Iceland) | Cardiovascular system (patho)physiology | 28 Aug 2011 |
| Electrophysiology in 2011: visions and challenges | Evolving medical antiarrhythmic treatment targets: ready for clinical practice? | DO.Arnar ( Reykjavik-Iceland) | Arrhythmias / Pacing / Resynchronisation | 28 Aug 2011 |
| Electrophysiology in 2011: visions and challenges | Prophylactic catheter ablation of VT in patients with structural heart disease: ready to reduce morality? | H.Kottkamp ( Zurich-Switzerland) | Arrhythmias / Pacing / Resynchronisation | 28 Aug 2011 |
| Electrophysiology in 2011: visions and challenges | Multimodality optimised lead positioning to reduce CRT non responders: ready for prime time? | OA.Breithardt ( Erlangen-Germany) | Arrhythmias / Pacing / Resynchronisation | 28 Aug 2011 |
| Novel approaches in hypertension | Neprilysin - the vasopeptidase comeback kid. | L M.Ruilope ( Madrid-Spain) | Hypertension | 28 Aug 2011 |
| Novel approaches in hypertension | Renal nerve ablation - ready for prime time? | H.Krum ( Melbourne-Australia) | Hypertension | 28 Aug 2011 |
| Novel approaches in hypertension | Aldosterone-synthase inhibitors. | F.Zannad ( Vandoeuvre Les Nancy-France) | Hypertension | 28 Aug 2011 |
| Novel approaches in hypertension | Third generation beta-blockers. | K.Stoschitzky ( Graz-Austria) | Hypertension | 28 Aug 2011 |
| Controversial issues in diabetes management | What is the target for HbA1C? | N.Marx ( Aachen-Germany) | Pharmacology and pharmacotherapy | 28 Aug 2011 |
| Controversial issues in diabetes management | When to use hypoglycaemic drugs? | E A M.Gale ( Bristol-United Kingdom) | Pharmacology and pharmacotherapy | 28 Aug 2011 |
| Controversial issues in diabetes management | Lipid-lowering therapy. How to get to target? | T R.Pedersen ( Oslo-Norway) | Pharmacology and pharmacotherapy | 28 Aug 2011 |
| Clinical Trial Update I - Drug treatment | KYOTO HEART Study: Cardiovascular protective effects of valsartan in high-risk hypertensive patients with chronic kidney disease: updated analysis of KYOTO HEART Study | T.Sawada ( Kyoto-Japan) | Hypertension | 28 Aug 2011 |
| Clinical Trial Update I - Drug treatment | Discussant - KYOTO HEART Study: Cardiovascular protective effects of valsartan in high-risk hypertensive patients with chronic kidney disease: updated analysis of KYOTO HEART Study | J.Redon ( Valencia-Spain) | Hypertension | 28 Aug 2011 |
| Clinical Trial Update I - Drug treatment | ASCOT: Anglo-Scandinavian Cardiac Outcomes Trial: 10 year follow-up of the Lipid_lowering Arml | P S.Sever ( London-United Kingdom) | Prevention and rehabilitation | 28 Aug 2011 |
| Clinical Trial Update I - Drug treatment | Discussant - ASCOT: Anglo-Scandinavian Cardiac Outcomes Trial: 10 year follow-up of the Lipid_lowering Arml | G.De Backer ( St Martens Latem-Belgium) | Prevention and rehabilitation | 28 Aug 2011 |
| Clinical Trial Update I - Drug treatment | ARISTOTLE: Efficacy and safety of Apixaban compared to Warfarin at different levels of INR control for stroke prevention in 18,202 patients with atrial fibrillation in the ARISTOTLE trial | L C.Wallentin ( Uppsala-Sweden) | Arrhythmias / Pacing / Resynchronisation | 28 Aug 2011 |
| Clinical Trial Update I - Drug treatment | ROCKET AF: Prevention of stroke and systemic embolism using the oral direct factor Xa inhibitor Rivaroxaban compared with Warfarin in patients with nonvalvular atrial fibrillation and moderate renal impairment | K A A.Fox ( Edinburgh-United Kingdom) | Arrhythmias / Pacing / Resynchronisation | 28 Aug 2011 |
| Clinical Trial Update I - Drug treatment | Discussant - ROCKET AF: Prevention of stroke and systemic embolism using the oral direct factor Xa inhibitor Rivaroxaban compared with Warfarin in patients with nonvalvular atrial fibrillation and moderate renal impairment | S H.Hohnloser ( Frankfurt-Germany) | Arrhythmias / Pacing / Resynchronisation | 28 Aug 2011 |
| Clinical Trial Update I - Drug treatment | RE-LY: Concomitant use of antiplatelet therapy with dabigatran or warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY®) trial | AM.Dans ( Manila-Philippines) | Arrhythmias / Pacing / Resynchronisation | 28 Aug 2011 |
| Clinical Trial Update I - Drug treatment | Discussant - RE-LY: Concomitant use of antiplatelet therapy with dabigatran or warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY®) trial | FWA.Verheugt ( Amsterdam-Netherlands) | Arrhythmias / Pacing / Resynchronisation | 28 Aug 2011 |
| Clinical Trial Update I - Drug treatment | ONTARGET: Medication adherence and outcomes in high-risk cardiovascular patients in the ONTARGET trial | M.Bohm ( Homburg/Saar-Germany) | Pharmacology and pharmacotherapy | 28 Aug 2011 |
| Clinical Trial Update I - Drug treatment | Discussant - ONTARGET: Medication adherence and outcomes in high-risk cardiovascular patients in the ONTARGET trial | L.Tavazzi ( Cotignola-Italy) | Pharmacology and pharmacotherapy | 28 Aug 2011 |
| Multimodality imaging heart failure | Role of echocardiography. | W G.Daniel ( Erlangen-Germany) | heart failure / LV dysfunction | 28 Aug 2011 |
| Multimodality imaging heart failure | Role of cardiac myocardial resonnance imaging. | M.Desai ( Cleveland-United States of America) | heart failure / LV dysfunction | 28 Aug 2011 |
| Multimodality imaging heart failure | Role of nuclear cardiology and cardiac computed tomography. | S R.Underwood ( London-United Kingdom) | heart failure / LV dysfunction | 28 Aug 2011 |
| Electrocardiogram - still a challenge? | Electrocardiogram tracings. | J L R M.Smeets ( Nijmegen-Netherlands) | Arrhythmias / Pacing / Resynchronisation | 28 Aug 2011 |
| Electrocardiogram - still a challenge? | Electrocardiogram tracings. | J.Brugada Terradellas ( Barcelona-Spain) | Arrhythmias / Pacing / Resynchronisation | 28 Aug 2011 |
| Imaging of the right ventricle | An unusual case of angina at rest. | M.Voehringer ( Stuttgart-Germany) | Nuclear cardiology, CMR & CT | 28 Aug 2011 |
| New features and effects of angiogenic growth factors in vascular diseases | VEGF splicing as control mechanism of angiogenesis in vascular diseases. | D.Bates ( Bristol-United Kingdom) | Vascular biology | 28 Aug 2011 |
| New features and effects of angiogenic growth factors in vascular diseases | VEGF-D as a vasculoprotective factor. | I.Zachary ( London-United Kingdom) | Vascular biology | 28 Aug 2011 |
| New features and effects of angiogenic growth factors in vascular diseases | VEGFs and the angiogenic paradox in diabetic patients. | J.Waltenberger ( Muenster-Germany) | Vascular biology | 28 Aug 2011 |
| Novel devices for heart failure | Current recommendations from the ESC Guidelines. | K.Dickstein ( Stavanger-Norway) | heart failure / LV dysfunction | 28 Aug 2011 |
| Novel devices for heart failure | Optimal application of telemonitoring. | A.Mortara ( Monza-Italy) | heart failure / LV dysfunction | 28 Aug 2011 |
| Novel devices for heart failure | Novel implantable devices for New York Heart Association I-III heart failure patients. | M R.Cowie ( London-United Kingdom) | heart failure / LV dysfunction | 28 Aug 2011 |
| Novel devices for heart failure | Devices for end-stage heart failure. | L.Warner Stevenson ( Boston-United States of America) | heart failure / LV dysfunction | 28 Aug 2011 |
| The challenge of arrhythmias in athletes | The frontier between normal and abnormal ectrocardiogram in athletes. | F.Carre ( Rennes Cedex-France) | Arrhythmias / Pacing / Resynchronisation | 28 Aug 2011 |
| The challenge of arrhythmias in athletes | Atrial fibrillation in athletes: clinical relevance and management. | L.Mont ( Barcelona-Spain) | Arrhythmias / Pacing / Resynchronisation | 28 Aug 2011 |
| The challenge of arrhythmias in athletes | Ventricular arrhythmias: who is at risk? | A.Steinvil ( Tel-Aviv-Israel) | Arrhythmias / Pacing / Resynchronisation | 28 Aug 2011 |
| The challenge of arrhythmias in athletes | Management of syncope in athletes. | L.Eckardt ( Munster-Germany) | Arrhythmias / Pacing / Resynchronisation | 28 Aug 2011 |
| Controversies in low-flow low-gradient aortic stenosis | Aortic valve replacement improves outcome in patients with preserved ejection fraction.: Pro. | P.Pibarot ( Quebec-Canada) | valvular disease | 28 Aug 2011 |
| Controversies in low-flow low-gradient aortic stenosis | Aortic valve replacement improves outcome in patients with preserved ejection fraction.: Contra. | G.Habib ( Marseille-France) | valvular disease | 28 Aug 2011 |
| Controversies in low-flow low-gradient aortic stenosis | Aortic valve replacement improves outcome in patients with preserved ejection fraction.: Pro. | P.Pibarot ( Quebec-Canada) | valvular disease | 28 Aug 2011 |
| Controversies in low-flow low-gradient aortic stenosis | Aortic valve replacement improves outcome in patients with preserved ejection fraction.: Contra. | G.Habib ( Marseille-France) | valvular disease | 28 Aug 2011 |
| Controversies in low-flow low-gradient aortic stenosis | Contractile reserve should be systematically assessed in patients with reduced ejection fraction: Pro. | J-L.Monin ( Creteil-France) | valvular disease | 28 Aug 2011 |
| Controversies in low-flow low-gradient aortic stenosis | Contractile reserve should be systematically assessed in patients with reduced ejection fraction.: Contra. | A A.Pasquet ( Brussels-Belgium) | valvular disease | 28 Aug 2011 |
| Controversies in low-flow low-gradient aortic stenosis | Contractile reserve should be systematically assessed in patients with reduced ejection fraction: Pro. | J-L.Monin ( Creteil-France) | valvular disease | 28 Aug 2011 |
| Controversies in low-flow low-gradient aortic stenosis | Contractile reserve should be systematically assessed in patients with reduced ejection fraction: Contra. | A A.Pasquet ( Brussels-Belgium) | valvular disease | 28 Aug 2011 |
| Dealing with major complications during percutaneous coronary intervention | Bleeding. | N.Meneveau ( Besancon-France) | Interventional cardiology | 28 Aug 2011 |
| Dealing with major complications during percutaneous coronary intervention | Thrombosis. | CKY.Wong ( Hong Kong-Hong Kong SAR, People's Republic of China) | Interventional cardiology | 28 Aug 2011 |
| Dealing with major complications during percutaneous coronary intervention | Device loss and foreign body retrieval. | A.Pichard ( Washington-United States of America) | Interventional cardiology | 28 Aug 2011 |
| Unprotected left main disease in 2011 | The spectrum of left main disease. | A.Chieffo ( Milan-Italy) | Interventional cardiology | 28 Aug 2011 |
| Unprotected left main disease in 2011 | Rationale for surgery. | J R.Pepper ( London-United Kingdom) | Interventional cardiology | 28 Aug 2011 |
| Unprotected left main disease in 2011 | Rationale for percutaneous revascularisation. | M C.Morice ( Massy-France) | Interventional cardiology | 28 Aug 2011 |
| Unprotected left main disease in 2011 | Future perspectives. | P W.Serruys ( Rotterdam-Netherlands) | Interventional cardiology | 28 Aug 2011 |
| CRH I - Risk and treatment reality | EUROACTION preventive cardiology programme plus intensive smoking cessation with Varenicline | D A.Wood ( London-United Kingdom) | Prevention and rehabilitation | 28 Aug 2011 |
| CRH I - Risk and treatment reality | EUROASPIRE III: modelling the clinical and cost-effectiveness of optimizing cardiovascular prevention in patients with established coronary heart disease in Europe | L.Annemans ( Gent-Belgium) | Prevention and rehabilitation | 28 Aug 2011 |
| CRH I - Risk and treatment reality | Quality of care at discharge is affected by hospital case volume in acute myocardial infarction patients. A French nationwide assessment | F.Schiele ( Besancon-France) | Epidemiology and health policy | 28 Aug 2011 |
| CRH I - Risk and treatment reality | "Atrial fibrillation ablation" European survey: short-term results. | J.Brugada Terradellas ( Barcelona-Spain) | Arrhythmias / Pacing / Resynchronisation | 28 Aug 2011 |
| CRH I - Risk and treatment reality | GARFIELD: Multicentre international registry of patients newly diagnosed with atrial fibrillation at risk of stroke: the Garfield Registry | A.Kakkar ( London-United Kingdom) | Peripheral circulation/stroke | 28 Aug 2011 |
| CRH I - Risk and treatment reality | Global variation in the etiology and management of atrial fibrillation: results from a global atrial fibrillation registry | J.Healey ( Hamilton-Canada) | Arrhythmias / Pacing / Resynchronisation | 28 Aug 2011 |
| Controversial issues in therapy | Should we test platelet response? | K.Schroer ( Dusseldorf-Germany) | Thrombosis & platelets, microcirculation | 28 Aug 2011 |
| Controversial issues in therapy | Antiplatelet regimens in patients undergoing percutaneous coronary intervention requiring anticoagulation. | A.Rubboli ( Bologna-Italy) | Thrombosis & platelets, microcirculation | 28 Aug 2011 |
| Controversial issues in therapy | Risk of gastrointestinal bleeding and use of proton pump inhibitors. | M.Sabatine ( Boston-United States of America) | Thrombosis & platelets, microcirculation | 28 Aug 2011 |
| Controversial issues in therapy | Risk of stopping dual therapy. | S D.Kristensen ( Aarhus N-Denmark) | Thrombosis & platelets, microcirculation | 28 Aug 2011 |
| The heart in concert: do other organs matter? | Gut. | A.Sandek ( Berlin-Germany) | heart failure / LV dysfunction | 28 Aug 2011 |
| The heart in concert: do other organs matter? | Bones. | P.Rozentryt ( Zabrze-Poland) | heart failure / LV dysfunction | 28 Aug 2011 |
| The heart in concert: do other organs matter? | Liver. | P.de Groote ( Lille Cedex-France) | heart failure / LV dysfunction | 28 Aug 2011 |
| Hot Line I - Cardiovascular risk and complications | PURE: The prevention gaps in 17 low, middle and high income countries involving over 150,000 people | S.Yusuf ( Hamilton-Canada) | Prevention and rehabilitation | 28 Aug 2011 |
| Hot Line I - Cardiovascular risk and complications | Discussant - PURE: The prevention gaps in 17 low, middle and high income countries involving over 150,000 people | A P.Maggioni ( Florence-Italy) | Prevention and rehabilitation | 28 Aug 2011 |
| Hot Line I - Cardiovascular risk and complications | HCS: Prospective evaluation of post-prandial triglycerides and cardiovascular events in patients with coronary artery disease | U.Laufs ( Homburg-Germany) | Prevention and rehabilitation | 28 Aug 2011 |
| Hot Line I - Cardiovascular risk and complications | Discussant - HCS: Prospective evaluation of post-prandial triglycerides and cardiovascular events in patients with coronary artery disease | P J.Barter ( Sydney-Australia) | Prevention and rehabilitation | 28 Aug 2011 |
| Hot Line I - Cardiovascular risk and complications | dal-VESSEL: Efficacy and safety of dalcetrapib in patients with or at risk of coronary heart disease - the dal-VESSEL trial | T F.Luescher ( Zurich-Switzerland) | Prevention and rehabilitation | 28 Aug 2011 |
| Hot Line I - Cardiovascular risk and complications | Discussant - dal-VESSEL: Efficacy and safety of dalcetrapib in patients with or at risk of coronary heart disease - the dal-VESSEL trial | K A A.Fox ( Edinburgh-United Kingdom) | Prevention and rehabilitation | 28 Aug 2011 |
| Hot Line I - Cardiovascular risk and complications | ARISTOTLE: Efficacy and safety of Apixaban compared to Warfarin for prevention of stroke and systemic embolism in 18,202 patients with atrial fibrillation: primary results of the ARISTOTLE trial | C B.Granger ( Durham-United States of America) | Arrhythmias / Pacing / Resynchronisation | 28 Aug 2011 |
| Hot Line I - Cardiovascular risk and complications | Discussant - ARISTOTLE: Efficacy and safety of Apixaban compared to Warfarin for prevention of stroke and systemic embolism in 18,202 patients with atrial fibrillation: primary results of the ARISTOTLE trial | M D.Ezekowitz ( Villanova-United States of America) | Arrhythmias / Pacing / Resynchronisation | 28 Aug 2011 |
| Hot Line I - Cardiovascular risk and complications | CORP: COlchicine for Recurrent Pericarditis (CORP). A multicenter, double-blind, randomized, controlled trial | M.Imazio ( Torino-Italy) | Myocardial-Pericardial disease | 28 Aug 2011 |
| Hot Line I - Cardiovascular risk and complications | Discussant - CORP: COlchicine for Recurrent Pericarditis (CORP). A multicenter, double-blind, randomized, controlled trial | A.Keren ( Jerusalem-Israel) | Myocardial-Pericardial disease | 28 Aug 2011 |
| Treating chronic heart failure comorbodities without harm: chronic kidney disease | Worsening renal function in heart failure; prognostic markers and effect of drugs. | M R.Cowie ( London-United Kingdom) | heart failure / LV dysfunction | 28 Aug 2011 |
| Treating chronic heart failure comorbodities without harm: chronic kidney disease | Tubular markers in heart failure; can we finally monitor renal function adequately? | C.Gaillard ( Bilthoven-Netherlands) | heart failure / LV dysfunction | 28 Aug 2011 |
| Treating chronic heart failure comorbodities without harm: chronic kidney disease | What do the Guidelines say? | D J.van Veldhuisen ( Groningen-Netherlands) | heart failure / LV dysfunction | 28 Aug 2011 |
| Cardiac resynchronisation therapy: from patient selection to monitorisation | The case of "non-left bundle branch block" QRS morphology: when should I consider cardiac resynchronisation therapy? | C.Linde ( Stockholm-Sweden) | Arrhythmias / Pacing / Resynchronisation | 28 Aug 2011 |
| Cardiac resynchronisation therapy: from patient selection to monitorisation | Recurrent atrial fibrillation in a cardiac resynchronisation therapy patient: role of remote monitoring for management strategy. | H.Burri ( Geneva-Switzerland) | Arrhythmias / Pacing / Resynchronisation | 28 Aug 2011 |
| Acute heart failure. Beyond conventional treatment? | Imposible diuresis. | E A.Lopez De Sa Y Areses ( Madrid-Spain) | heart failure / LV dysfunction | 28 Aug 2011 |
| Acute heart failure. Beyond conventional treatment? | Persisting low output. | A.Mebazaa ( Paris Cedex 10-France) | heart failure / LV dysfunction | 28 Aug 2011 |
| Acute heart failure. Beyond conventional treatment? | What do the Guidelines say? | J L.Lopez-Sendon ( Madrid-Spain) | heart failure / LV dysfunction | 28 Aug 2011 |
| Hypertension and diabetes - deadly challenge | Uncomplicated hypertension with diabetes: when and how to treat? | P M.Nilsson ( Dalby-Sweden) | Hypertension | 28 Aug 2011 |
| Hypertension and diabetes - deadly challenge | Hypertension with diabetic nephropathy: how to manage? | J.Redon ( Valencia-Spain) | Hypertension | 28 Aug 2011 |
| Hypertension and diabetes - deadly challenge | What do the Guidelines say? | R.Fagard ( Leuven-Belgium) | Hypertension | 28 Aug 2011 |
| Treating hypertension in difficult settings | A 53-year-old woman with difficult to control hypertension. | Y.Uresin ( Istanbul-Turkey) | Hypertension | 28 Aug 2011 |
| Treating hypertension in difficult settings | A 72-year-old woman with hypertension and severe dyspnea on moderate exertion. | M.Galderisi ( Naples-Italy) | Hypertension | 28 Aug 2011 |
| Treating hypertension in difficult settings | What do the Guidelines say? | V.Sansoy ( Istanbul-Turkey) | Hypertension | 28 Aug 2011 |
| Managing difficult pulmonary embolism | Interventional management of acute pulmonary embolism. | N.Kucher ( Bern-Switzerland) | pulmonary circulation | 28 Aug 2011 |
| Managing difficult pulmonary embolism | Acute pulmonary embolism: a challenging management decision. | C.Kupatt ( Munich-Germany) | pulmonary circulation | 28 Aug 2011 |
| Managing difficult pulmonary embolism | What do the Guidelines say? | N.Meneveau ( Besancon-France) | pulmonary circulation | 28 Aug 2011 |
| Percutaneous valve implantation or operation in aortic stenosis? | A patient with severe aortic stenosis and coronary artery disease. | U O.von Oppell ( Cardiff-United Kingdom) | valvular disease | 28 Aug 2011 |
| Percutaneous valve implantation or operation in aortic stenosis? | A patient with severe aortic stenosis and severe left ventricular dysfunction. | H.Baumgartner ( Muenster-Germany) | valvular disease | 28 Aug 2011 |
| Decision making in patients with multivalvular disease | A patient with a combined aortic stenotic and regurgitant lesion. | J-L.Monin ( Creteil-France) | valvular disease | 28 Aug 2011 |
| Decision making in patients with multivalvular disease | What do the Guidelines say? | R.Rosenhek ( Vienna-Austria) | valvular disease | 28 Aug 2011 |
| New evidence beyond guidelines in atrial fibrillation | New developments in the diagnosis of atrial fibrillation. | G.Hindricks ( Leipzig-Germany) | Arrhythmias / Pacing / Resynchronisation | 29 Aug 2011 |
| New evidence beyond guidelines in atrial fibrillation | New antithrombotic therapies: revisiting stroke prevention in atrial fibrillation. | L C.Wallentin ( Uppsala-Sweden) | Arrhythmias / Pacing / Resynchronisation | 29 Aug 2011 |
| New evidence beyond guidelines in atrial fibrillation | Will catheter ablation of atrial fibrillation withstand the test of randomised studies. | S.Ernst ( London-United Kingdom) | Arrhythmias / Pacing / Resynchronisation | 29 Aug 2011 |
| Take home messages from recent heart failure clinical trials | How to use aldosterone blockers. | F.Zannad ( Vandoeuvre Les Nancy-France) | heart failure / LV dysfunction | 29 Aug 2011 |
| Take home messages from recent heart failure clinical trials | Heart rate as a target. | JS.Borer ( New York-United States of America) | heart failure / LV dysfunction | 29 Aug 2011 |
| Take home messages from recent heart failure clinical trials | Current indications for resynchronisation therapy. | P E.Vardas ( Heraklion-Greece) | heart failure / LV dysfunction | 29 Aug 2011 |
| Take home messages from recent heart failure clinical trials | Telemonitoring in clinical practice. | F.Koehler ( Berlin-Germany) | heart failure / LV dysfunction | 29 Aug 2011 |
| 2011 Guidelines overview | Peripheral artery disease. | M.Tendera ( Katowice-Poland) - V.Aboyans ( Limoges-France) | Peripheral circulation/stroke | 29 Aug 2011 |
| 2011 Guidelines overview | Acute coronary syndrome and non ST-elevation. | C W.Hamm ( Bad Nauheim-Germany) - J-P.Bassand ( Besancon Cedex-France) | Ischaemia / ACS / infarction | 29 Aug 2011 |
| 2011 Guidelines overview | Cardiovascular disease during pregnancy. | V.Regitz-Zagrosek ( Berlin-Germany) | Congenital heart disease / Pediatric cardiology | 29 Aug 2011 |
| 2011 Guidelines overview | Dyslipidemias. | Z.Reiner ( Zagreb-Croatia) | Pharmacology and pharmacotherapy | 29 Aug 2011 |
| Does the presence of chronic kidney disease modify the advice of guidelines? | Impact on pharmacology of cardiovascular drugs. | L M.Ruilope ( Madrid-Spain) | Pharmacology and pharmacotherapy | 29 Aug 2011 |
| Does the presence of chronic kidney disease modify the advice of guidelines? | In hypertension. | E.Ritz ( Heidelberg-Germany) | Pharmacology and pharmacotherapy | 29 Aug 2011 |
| Does the presence of chronic kidney disease modify the advice of guidelines? | In heart failure. | M R.Cowie ( London-United Kingdom) | Pharmacology and pharmacotherapy | 29 Aug 2011 |
| Does the presence of chronic kidney disease modify the advice of guidelines? | In acute coronary syndrome. | D.Zahger ( Beer Sheva-Israel) | Pharmacology and pharmacotherapy | 29 Aug 2011 |
| What should the general cardiologist know about grown-up congenital heart disease? | Management of the cyanotic patient. | L.Swan ( London-United Kingdom) | Congenital heart disease / Pediatric cardiology | 29 Aug 2011 |
| What should the general cardiologist know about grown-up congenital heart disease? | Marfan Syndrome. | H.Kaemmerer ( Muenchen-Germany) | Congenital heart disease / Pediatric cardiology | 29 Aug 2011 |
| Hot Line II - Frontiers in interventional and device treatments | ECOST: Safety of implantable cardioverter defibrillator follow-up using remote monitoring: a randomized controlled trial | S.Kacet ( Lille Cedex-France) | Arrhythmias / Pacing / Resynchronisation | 29 Aug 2011 |
| Hot Line II - Frontiers in interventional and device treatments | Discussant - ECOST: Safety of implantable cardioverter defibrillator follow-up using remote monitoring: a randomized controlled trial | J C.Daubert ( Rennes-France) | Arrhythmias / Pacing / Resynchronisation | 29 Aug 2011 |
| Hot Line II - Frontiers in interventional and device treatments | Discussant - EMPHASIS-HF. The effect of eplerenone versus placebo on cardiovascular mortality or heart failure hospitalization in subjects with NYHA class II chronic systolic heart failure: An analysis of the High-risk groups in the study population | P. Ponikowwski (Wroclaw, Poland) | heart failure / LV dysfunction | 29 Aug 2011 |
| Hot Line II - Frontiers in interventional and device treatments | RESET: One-year outcome of the Randomized Evaluation of Sirolimus-eluting versus Everolimus-eluting stent Trial | T.Kimura ( Kyoto-Japan) | Interventional cardiology | 29 Aug 2011 |
| Hot Line II - Frontiers in interventional and device treatments | Discussant - RESET: One-year outcome of the Randomized Evaluation of Sirolimus-eluting versus Everolimus-eluting stent Trial | S.Windecker ( Bern-Switzerland) | Interventional cardiology | 29 Aug 2011 |
| Hot Line II - Frontiers in interventional and device treatments | Comparison of three-year outcome after PCI and CABG stratified by the SYNTAX score in patients with triple vessel coronary artery disease: an observation from the CREDO-Kyoto PCI/CABG registry Cohort-2 | H.Shiomi ( Kyoto-Japan) | Interventional cardiology | 29 Aug 2011 |
| Hot Line II - Frontiers in interventional and device treatments | Discussant - Comparison of three-year outcome after PCI and CABG stratified by the SYNTAX score in patients with triple vessel coronary artery disease: an observation from the CREDO-Kyoto PCI/CABG registry Cohort-2 | F.Van de Werf ( Leuven-Belgium) | Interventional cardiology | 29 Aug 2011 |
| Challenges in diagnosis and management of unusual familial cardiomyopathies | A case of hypertrophic cardiomyopathy with left bundle branch block and severe heart failure. | C.Rapezzi ( Bologna-Italy) | Myocardial-Pericardial disease | 29 Aug 2011 |
| Challenges in diagnosis and management of unusual familial cardiomyopathies | What do the Guidelines say? | A.Keren ( Jerusalem-Israel) | Myocardial-Pericardial disease | 29 Aug 2011 |
| Optimising antithrombotic therapy: a tailored approach? | Tailored antithrombotic therapy in non ST-elevation-acute coronary syndrome. | P G.Steg ( Paris Cedex 18-France) | Ischaemia / ACS / infarction | 29 Aug 2011 |
| Optimising antithrombotic therapy: a tailored approach? | What do the Guidelines say? | N.Danchin ( Paris-France) | Ischaemia / ACS / infarction | 29 Aug 2011 |
| Anti-thrombotic therapy in atrial fibrillation - difficult management scenarios | Stroke and bleeding risk assessment in a high risk atrial fibrillation patient who needs a coronary stent. | A.Rubboli ( Bologna-Italy) | Arrhythmias / Pacing / Resynchronisation | 29 Aug 2011 |
| Anti-thrombotic therapy in atrial fibrillation - difficult management scenarios | The 'truly low stroke risk' patient with atrial fibrillation: defining the population and what to do post-ablation. | L.Fauchier ( Tours-France) | Arrhythmias / Pacing / Resynchronisation | 29 Aug 2011 |
| ESC Guidelines on the diagnosis and treatment of peripheral artery diseases | Scope of the problem. | G.Fowkes ( Edinburgh-United Kingdom) | Peripheral circulation/stroke | 29 Aug 2011 |
| ESC Guidelines on the diagnosis and treatment of peripheral artery diseases | Cerebral artery disease. | M R H M.Van Sambeek ( Eindhoven-Netherlands) | Peripheral circulation/stroke | 29 Aug 2011 |
| ESC Guidelines on the diagnosis and treatment of peripheral artery diseases | Mesenteric and renal artery disease. | T.Zeller ( Bad Krozingen-Germany) | Peripheral circulation/stroke | 29 Aug 2011 |
| ESC Guidelines on the diagnosis and treatment of peripheral artery diseases | Lower extremity artery disease. | E.Minar ( Vienna-Austria) | Peripheral circulation/stroke | 29 Aug 2011 |
| ESC Guidelines on the diagnosis and treatment of peripheral artery diseases | Multisite disease. | H.Sievert ( Frankfurt-Germany) | Peripheral circulation/stroke | 29 Aug 2011 |
| ESC Guidelines on the diagnosis and treatment of peripheral artery diseases | Closing remarks. | V.Aboyans ( Limoges-France) | Peripheral circulation/stroke | 29 Aug 2011 |
| Controversial issues in cardiac resynchronisation therapy | Is the optimisation of the atrioventricular and interventricular delays useful? | D.Gras ( Nantes Cedex 2-France) | Arrhythmias / Pacing / Resynchronisation | 29 Aug 2011 |
| Controversial issues in cardiac resynchronisation therapy | How to manage cardiac resynchronisation therapy in atrial fibrillation patients? | E K.Heist ( Boston-United States of America) | Arrhythmias / Pacing / Resynchronisation | 29 Aug 2011 |
| Controversial issues in cardiac resynchronisation therapy | The use of cardiac resynchronisation therapy outside current guidelines. | RJ.van Bommel ( Leiden-Netherlands) | Arrhythmias / Pacing / Resynchronisation | 29 Aug 2011 |
| Nurse-led prevention: why is it not implemented in Europe yet? | Effectiveness in the RESPONSE trial. | R J G.Peters ( Amsterdam-Netherlands) | Prevention and rehabilitation | 29 Aug 2011 |
| Nurse-led prevention: why is it not implemented in Europe yet? | Feasibility in the EUROACTION study. | C S.Jennings ( London-United Kingdom) | Prevention and rehabilitation | 29 Aug 2011 |
| Nurse-led prevention: why is it not implemented in Europe yet? | Should we only focus on nurse-led programmes? | J.Perk ( Kalmar-Sweden) | Prevention and rehabilitation | 29 Aug 2011 |
| Nurse-led prevention: why is it not implemented in Europe yet? | Do we know how to do it? | N.Houston-Miller ( Stanford-United States of America) | Prevention and rehabilitation | 29 Aug 2011 |
| Hot topics in echocardiography: the position of the European Association of Echocardiography | ASE/EAE recommendations about echo assessment of left ventricular mechanics. | J U.Voigt ( Leuven-Belgium) | Echocardiography / Doppler | 29 Aug 2011 |
| Hot topics in echocardiography: the position of the European Association of Echocardiography | EAE position paper on pocket size imaging devices. | R.Sicari ( Pisa-Italy) | Echocardiography / Doppler | 29 Aug 2011 |
| Hot topics in echocardiography: the position of the European Association of Echocardiography | EAE recommendations about the use of echo in Emergency Department. | A.Hagendorff ( Leipzig-Germany) | Echocardiography / Doppler | 29 Aug 2011 |
| The very latest on carotid stenting | Natural history. | P.Poredos ( Ljubljana-Slovenia) | Peripheral circulation/stroke | 29 Aug 2011 |
| The very latest on carotid stenting | When to intervene. | A.Cremonesi ( Cotignola-Italy) | Peripheral circulation/stroke | 29 Aug 2011 |
| The very latest on carotid stenting | Rationale for surgery. | P.Bergeron ( Marseille-France) | Peripheral circulation/stroke | 29 Aug 2011 |
| The very latest on carotid stenting | Rationale for stenting. | M.Roffi ( Geneva 14-Switzerland) | Peripheral circulation/stroke | 29 Aug 2011 |
| Clinical Trial Update II - Rate and rhythm | SMART-AV: The role of electrical delay (QLV) to predict left ventricular reverse remodeling with cardiac resynchronization therapy | M R.Gold ( Charleston-United States of America) | heart failure / LV dysfunction | 29 Aug 2011 |
| Clinical Trial Update II - Rate and rhythm | Discussant - SMART-AV: The role of electrical delay (QLV) to predict left ventricular reverse remodeling with cardiac resynchronization therapy | C.Linde ( Stockholm-Sweden) | heart failure / LV dysfunction | 29 Aug 2011 |
| Clinical Trial Update II - Rate and rhythm | PACE: Biventricular pacing superior to right ventricular pacing in bradycardia patients with preserved systolic function: two-year results of PACE trial | CM.Yu ( Hong Kong-Hong Kong SAR, People's Republic of China) | Arrhythmias / Pacing / Resynchronisation | 29 Aug 2011 |
| Clinical Trial Update II - Rate and rhythm | Discussant - PACE: Biventricular pacing superior to right ventricular pacing in bradycardia patients with preserved systolic function: two-year results of PACE trial | K.Dickstein ( Stavanger-Norway) | Arrhythmias / Pacing / Resynchronisation | 29 Aug 2011 |
| Clinical Trial Update II - Rate and rhythm | Discussant - IRIS: Why does the implantable cardioverter-defibrillator not improve mortality early after myocardial infarction - Insights from the Immediate Risk Stratification Improves Survival (IRIS) trial | C.Leclercq ( Rennes-France) | Arrhythmias / Pacing / Resynchronisation | 29 Aug 2011 |
| Clinical Trial Update II - Rate and rhythm | SHIFT: Relationship between heart rate and health related quality of life. Results from SHIFT | I.Ekman ( Goteborg-Sweden) | heart failure / LV dysfunction | 29 Aug 2011 |
| Clinical Trial Update II - Rate and rhythm | Discussant - SHIFT: Relationship between heart rate and health related quality of life. Results from SHIFT | E.Erdmann ( Koeln-Germany) | heart failure / LV dysfunction | 29 Aug 2011 |
| Clinical Trial Update II - Rate and rhythm | SHIFT: Selective heart rate reduction with Ivabradine improves left ventricular remodeling and function: insights from the SHIFT-Echocardiography sub-study | J-C.Tardif ( Montreal-Canada) | heart failure / LV dysfunction | 29 Aug 2011 |
| Clinical Trial Update II - Rate and rhythm | Discussant - SHIFT: Selective heart rate reduction with Ivabradine improves left ventricular remodeling and function: insights from the SHIFT-Echocardiography sub-study | B M.Pieske ( Graz-Austria) | heart failure / LV dysfunction | 29 Aug 2011 |
| Clinical Trial Update II - Rate and rhythm | Discussant - STICH: Influence of mitral valve repair on survival in the surgical treatment for Ischemic heart failure trial | A.Vahanian ( Paris-France) | heart failure / LV dysfunction | 29 Aug 2011 |
| Convergence of generations in myocardial infarction management: from 'old' therapies to 'new' technologies | 'Old Therapies': how was myocardial infarction management in 1970? | G.Breithardt ( Munster-Germany) | Ischaemia / ACS / infarction | 29 Aug 2011 |
| Convergence of generations in myocardial infarction management: from 'old' therapies to 'new' technologies | Future therapies for myocardial infarction in 2050: cells, genetics and pharmacogenomics. | V.Fuster ( New York-United States of America) | Ischaemia / ACS / infarction | 29 Aug 2011 |
| Convergence of generations in myocardial infarction management: from 'old' therapies to 'new' technologies | Future interventional therapies and new devices for myocardial infarction in 2050. | F.Van de Werf ( Leuven-Belgium) | Ischaemia / ACS / infarction | 29 Aug 2011 |
| Difficult echocardiography in congenital heart disease | Difficult echocardiography in an adult patient previously unknown to have congenital heart disease. | L.Iserin ( Paris Cedex 15-France) | Congenital heart disease / Pediatric cardiology | 29 Aug 2011 |
| Difficult echocardiography in congenital heart disease | Difficult echocardiography in an adult patient with repaired congenital heart disease. | B J.Bouma ( Amsterdam-Netherlands) | Congenital heart disease / Pediatric cardiology | 29 Aug 2011 |
| Multimodality imaging in valvular heart disease | Role of 2D and 3D echo in aortic stenosis- Tips and tricks. | S.Sengupta ( Nagpur-India) | Echocardiography / Doppler | 29 Aug 2011 |
| Multimodality imaging in valvular heart disease | Is there a role for computed tomography/myocardial magnetic resonnance imaging in aortic stenosis ? | C.Zito ( Messina-Italy) | Echocardiography / Doppler | 29 Aug 2011 |
| Assessment of myocardial viability | Integration of coronary anatomy, function, perfusion and metabolism. | A.Saraste ( Turku-Finland) | Nuclear cardiology, CMR & CT | 29 Aug 2011 |
| Assessment of myocardial viability | Myocardial characterisation using cardiovascular magnetic resonnance. | E.Nagel ( London-United Kingdom) | Nuclear cardiology, CMR & CT | 29 Aug 2011 |
| Invasive coronary imaging in daily practice | Optical coherence tomography in acute coronary syndrome. | G.Guagliumi ( Bergamo-Italy) | Coronary circulation | 29 Aug 2011 |
| Invasive coronary imaging in daily practice | Intravascular ultrasound to optimize percutaneous intervention results. | A.Abizaid ( Sao Paulo-Brazil) | Coronary circulation | 29 Aug 2011 |
| State of the Art - Leucocytes and macrophages in Atherosclerosis: fuel for the fire | New therapy for atherosclerosis targeting folate receptor-beta expressing macrophages | Y.Furusho ( Kagoshima-Japan) | Vascular biology | 29 Aug 2011 |
| State of the Art - Leucocytes and macrophages in Atherosclerosis: fuel for the fire | Effector memory T cells are related to the atherosclerotic process in humans and murine models | E.Ammirati ( Milan-Italy) | Vascular biology | 29 Aug 2011 |
| State of the Art - Leucocytes and macrophages in Atherosclerosis: fuel for the fire | Essential role of CD4 T cells in Angiotensin II-induced atherosclerosis and vulnerable atherosclerotic plaque development | M.Pellegrin ( Lausanne-Switzerland) | Vascular biology | 29 Aug 2011 |
| State of the Art - Leucocytes and macrophages in Atherosclerosis: fuel for the fire | MicroRNA expression in peripheral blood monocytes in different stages of atherosclerosis development in humans | KL.Daum ( Giessen-Germany) | Vascular biology | 29 Aug 2011 |
| Novel aspects of channelopathies: from development to adult life | Sodium channelopathies in the developing heart - a key to understanding adult arrhythmogenesis. | A.Aranega Jimenez ( Jaen-Spain) | Cardiac cellular biology | 29 Aug 2011 |
| Novel aspects of channelopathies: from development to adult life | Linking Pitx2 insufficiency to atrial fibrillation. | P.Kirchhof ( Munster-Germany) | Cardiac cellular biology | 29 Aug 2011 |
| Novel aspects of channelopathies: from development to adult life | Brugada syndrome: a developmental perspective. | C A.Remme ( Amsterdam Z0-Netherlands) | Cardiac cellular biology | 29 Aug 2011 |
| Novel aspects of channelopathies: from development to adult life | Calcium channelopathies: current appraisal and future hopes. | S G.Priori ( Pavia-Italy) | Cardiac cellular biology | 29 Aug 2011 |
| State of the Art - Probing prognosis in heart failure | Predicting survival in chronic heart failure: a risk score based on 47886 patients from 31 studies | S J.Pocock ( London-United Kingdom) | heart failure / LV dysfunction | 29 Aug 2011 |
| State of the Art - Probing prognosis in heart failure | Prognostic value of baseline NT-proBNP and its interactions with irbesartan treatment in patients with heart failure and preserved ejection fraction: Findings from the I-PRESERVE trial | I S.Anand ( Edina-United States of America) | heart failure / LV dysfunction | 29 Aug 2011 |
| State of the Art - Probing prognosis in heart failure | Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure. Results from two large randomized clinical trials | S.Masson ( Milan-Italy) | heart failure / LV dysfunction | 29 Aug 2011 |
| State of the Art - Probing prognosis in heart failure | State of the Art - Probing prognosis in heart failure | D R .Wagner ( Luxembourg-Luxembourg) | heart failure / LV dysfunction | 29 Aug 2011 |
| State of the Art - Featured research on genetic aspects of cardiac arrhythmias | A rare variant in MYH6 confers high risk of sick sinus syndrome | H.Holm ( Mosfellsbaer-Iceland) | Arrhythmias / Pacing / Resynchronisation | 29 Aug 2011 |
| State of the Art - Featured research on genetic aspects of cardiac arrhythmias | A dominant negative missense mutation in MOG1 induces trafficking defect of cardiac sodium channel and is associated with Brugada syndrome ECG pattern | D.Kattygnarath ( Paris-France) | Arrhythmias / Pacing / Resynchronisation | 29 Aug 2011 |
| State of the Art - Featured research on genetic aspects of cardiac arrhythmias | State of the Art - Featured research on genetic aspects of cardiac arrhythmias | P J.Schwartz ( Pavia-Italy) | Arrhythmias / Pacing / Resynchronisation | 29 Aug 2011 |
| New non ST-elevation-acute coronary syndrome Guidelines | Introduction. | C W.Hamm ( Bad Nauheim-Germany) | Ischaemia / ACS / infarction | 29 Aug 2011 |
| New non ST-elevation-acute coronary syndrome Guidelines | Diagnosis and risk stratification. | H.Bueno ( Madrid-Spain) | Ischaemia / ACS / infarction | 29 Aug 2011 |
| New non ST-elevation-acute coronary syndrome Guidelines | Antiplatelet and anticoagulation treatment. | R F.Storey ( Sheffield-United Kingdom) | Ischaemia / ACS / infarction | 29 Aug 2011 |
| New non ST-elevation-acute coronary syndrome Guidelines | Invasive management. | D.Dudek ( Krakow-Poland) | Ischaemia / ACS / infarction | 29 Aug 2011 |
| State of the Art - Can we cure resistant hypertension? | Sympathetic nerve traffic, insulin resistance and baroreflex control of circulation in patients with resistant hypertension. | G.Seravalle ( Milan-Italy) | Hypertension | 29 Aug 2011 |
| State of the Art - Can we cure resistant hypertension? | Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial | J.Vaclavik ( Olomouc-Czech Republic) | Hypertension | 29 Aug 2011 |
| State of the Art - Can we cure resistant hypertension? | Confirmation of sustainability of hemodynamic response to baroreflex activation therapy in patients with resistant hypertension | C.Kaufman ( Minneapolis-United States of America) | Hypertension | 29 Aug 2011 |
| State of the Art - Can we cure resistant hypertension? | Effects of percutaneous renal denervation in patients with resistant hypertension on ambulatory blood pressure measurement and dipping | T.Lambert ( Linz-Austria) | Hypertension | 29 Aug 2011 |
| State of the Art - Can we cure resistant hypertension? | State of the Art - Can we cure resistant hypertension? | S.Laurent ( Paris-France) | Hypertension | 29 Aug 2011 |
| State of the Art - Tobacco use, no smoke without fire | Smoking and obesity/overweight: relations to all-cause mortality and major cardiovascular in a population-based cohort of men and women | G.Nilsson ( Vasteras-Sweden) | Epidemiology and health policy | 29 Aug 2011 |
| State of the Art - Tobacco use, no smoke without fire | Smokeless tobacco (snus) and mortality after myocardial infarction | G.Arefalk ( Uppsala-Sweden) | Epidemiology and health policy | 29 Aug 2011 |
| State of the Art - Tobacco use, no smoke without fire | Reduced incidence of ST-elevation myocardial infarction in the first two years after introduction of a public smoking ban in canton ticino, switzerland | M.Di Valentino ( Bellinzona-Switzerland) | Epidemiology and health policy | 29 Aug 2011 |
| State of the Art - Tobacco use, no smoke without fire | Smoking relapse and mortality after acute coronary syndromes | F.Colivicchi ( Rome-Italy) | Prevention and rehabilitation | 29 Aug 2011 |
| State of the Art - Tobacco use, no smoke without fire | State of the Art - Tobacco use, no smoke without fire. | C.Pisinger ( Glostrup-Denmark) | Epidemiology and health policy | 29 Aug 2011 |
| Strategies for smoking cessation: policy and practice | Persistent smoking in high-risk patients - the reality in clinical practice and how to improve. | K.Kotseva ( London-United Kingdom) | Prevention and rehabilitation | 29 Aug 2011 |
| Strategies for smoking cessation: policy and practice | Strategies for smoking cessation - evidence from trials. | D A.Wood ( London-United Kingdom) | Prevention and rehabilitation | 29 Aug 2011 |
| State of the Art - Pathobiological changes in pulmonary arterial hypertension | Right ventricular adaptation to pressure load in mice is improved after blockade of calcineurin activation | B.Bartelds ( Groningen-Netherlands) | pulmonary circulation | 29 Aug 2011 |
| State of the Art - Pathobiological changes in pulmonary arterial hypertension | Baseline difference in transcriptional patterns between PAH patients and normal volunteers | S.Cantoni ( Bologna-Italy) | pulmonary circulation | 29 Aug 2011 |
| State of the Art - Pathobiological changes in pulmonary arterial hypertension | Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension | B.Girerd ( Clamart-France) | pulmonary circulation | 29 Aug 2011 |
| State of the Art - Pathobiological changes in pulmonary arterial hypertension | State of the Art - Pathobiological changes in pulmonary arterial hypertension | M.Humbert ( Clamart Cedex-France) | valvular disease | 29 Aug 2011 |
| Imaging pericardial disease: update 2011 | Echocardiography. | P P.Sengupta ( Irvine-United States of America) | Nuclear cardiology, CMR & CT | 29 Aug 2011 |
| Imaging pericardial disease: update 2011 | Multidetector computed tomography. | S.Achenbach ( Erlangen-Germany) | Nuclear cardiology, CMR & CT | 29 Aug 2011 |
| Imaging pericardial disease: update 2011 | Invasive diagnostic procedures. | A D.Ristic ( Belgrade-Serbia) | Nuclear cardiology, CMR & CT | 29 Aug 2011 |
| State of the Art - New twists in cardiovascular imaging | Transforming growth factor is linked to abnormal collagen turnover leading to impaired myocardial deformation in untreated hypertensives | I.Ikonomidis ( Athens-Greece) | Echocardiography / Doppler | 29 Aug 2011 |
| State of the Art - New twists in cardiovascular imaging | Global two-dimensional strain as a novel parameter of myocardial fibrosis, and the assessment of risk for major cardiac events in patients with hypertrophic cardiomyopathy | M.Saito ( Ozu-Japan) | Echocardiography / Doppler | 29 Aug 2011 |
| State of the Art - New twists in cardiovascular imaging | Association of imaging markers of myocardial fibrosis with metabolic and functional disturbances in early diabetic cardiomyopathy: a multi-modality study | C.Jellis ( Camp Hill-Australia) | Nuclear cardiology, CMR & CT | 29 Aug 2011 |
| State of the Art - New twists in cardiovascular imaging | Epicardial fat volume on non-contrast computed tomography is associated with high-risk coronary artery plaque features | R.Rajani ( London-United Kingdom) | Nuclear cardiology, CMR & CT | 29 Aug 2011 |
| State of the Art - Antiplatelet therapy: clinical, genetic and platelet determinants of risk | Platelet reactivity on clopidogrel therapy and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent pharmacodynamic analysis of the GRAVITAS trial | M.Price ( La Jolla-United States of America) | Thrombosis & platelets, microcirculation | 29 Aug 2011 |
| State of the Art - Antiplatelet therapy: clinical, genetic and platelet determinants of risk | Impact of the cytochrome P450 2C19*3 polymorphism on platelet reactivity and adverse clinical events in patients with acute myocardial infarction | YH.Jeong ( Baltimore-United States of America) | Thrombosis & platelets, microcirculation | 29 Aug 2011 |
| CRH II - Interventions and devices | The Italian Elderly ACS study: Early aggressive versus initially conservative strategy in elderly patients with non-ST- elevation acute coronary syndrome: the Italian Elderly ACS randomised trial (ClinicalTrials.gov ID: NCT00510185) | S.Savonitto ( Milano-Italy) | Ischaemia / ACS / infarction | 29 Aug 2011 |
| CRH II - Interventions and devices | Is clopidogrel discontinuation following acute coronary syndrome hospitalisation associated with a higher risk of death and myocardial infarction? | A D.Timmis ( London-United Kingdom) | Ischaemia / ACS / infarction | 29 Aug 2011 |
| CRH II - Interventions and devices | The PACIFIC registry: one-year follow-up data of a 2-Year study in patients initially hospitalised with ACS | K.Miyauchi ( Tokyo-Japan) | Interventional cardiology | 29 Aug 2011 |
| CRH II - Interventions and devices | The European CRT survey: 1 year follow-up results | N.Bogale ( Sandnes-Norway) | Arrhythmias / Pacing / Resynchronisation | 29 Aug 2011 |
| CRH II - Interventions and devices | FRANCE II: French registry aortic national corevalve and Edwards registry II | M.Gilard ( Brest Cedex-France) | valvular disease | 29 Aug 2011 |
| State of the Art - Old challenges in interventional cardiology: new answers from very large multicenter studies | Considerably lower risk of stent thrombosis and restenosis in "new generation" drug-eluting stents: a report from the nation wide complete Swedish Coronary Angiography and Angioplasty Registry (SCAAR) | G.Sarno ( Uppsala-Sweden) | Interventional cardiology | 29 Aug 2011 |
| State of the Art - Old challenges in interventional cardiology: new answers from very large multicenter studies | Longterm clinical outcomes and duration of dual antiplatelet therapy after drug-eluting stent implantation: landmark analyses from CREDO-KYOTO Cohort-2 registry | T.Tada ( Munchen-Germany) | Interventional cardiology | 29 Aug 2011 |
| State of the Art - Old challenges in interventional cardiology: new answers from very large multicenter studies | Primary percutaneous coronary intervention as a national reperfusion strategy in patients with ST-elevation myocardial infarction: eleven years of experience from the western denmark heart registry. | C J.Terkelsen ( Aarhus-Denmark) | Interventional cardiology | 29 Aug 2011 |
| State of the Art - Old challenges in interventional cardiology: new answers from very large multicenter studies | Improved two-year outcomes of STEMI patients treated with drug-eluting compared with bare-metal stents. Experiences from the randomized BASKET-PROVE trial | S.Pedersen ( Hellerup-Denmark) | Interventional cardiology | 29 Aug 2011 |
| State of the Art - Old challenges in interventional cardiology: new answers from very large multicenter studies | State of the Art - Old challenges in interventional cardiology: new answers from very large multicenter studies | E M.Antman ( Boston-United States of America) | Coronary circulation | 29 Aug 2011 |
| ESC Guidelines for the management of cardiovascular diseases during pregnancy | New aspects in the pregnancy guidelines. | V.Regitz-Zagrosek ( Berlin-Germany) | Congenital heart disease / Pediatric cardiology | 30 Aug 2011 |
| ESC Guidelines for the management of cardiovascular diseases during pregnancy | Identification and management of the high-risk patient. | J W.Roos-Hesselink ( Rotterdam-Netherlands) | Congenital heart disease / Pediatric cardiology | 30 Aug 2011 |
| ESC Guidelines for the management of cardiovascular diseases during pregnancy | Which arrhythmias need treatment. | C.Blomstrom-Lundqvist ( Uppsala-Sweden) | Congenital heart disease / Pediatric cardiology | 30 Aug 2011 |
| ESC Guidelines for the management of cardiovascular diseases during pregnancy | How to manage anticoagulation in pregnant women. | P G.Pieper ( Groningen-Netherlands) | Congenital heart disease / Pediatric cardiology | 30 Aug 2011 |
| Can the polypill save the world? | Cardiovascular prevention; a global problem. | U.Keil ( Muenster-Germany) | Prevention and rehabilitation | 30 Aug 2011 |
| Can the polypill save the world? | Polypill for primary prevention. | S.Yusuf ( Hamilton-Canada) | Prevention and rehabilitation | 30 Aug 2011 |
| Can the polypill save the world? | Polypill for secondary prevention. | V.Fuster ( New York-United States of America) | Prevention and rehabilitation | 30 Aug 2011 |
| Can the polypill save the world? | Alternatives to polypills. | AJ.Taylor ( Washington-United States of America) | Prevention and rehabilitation | 30 Aug 2011 |
| Controversial issues on transcatheter aortic valve implantation | What are the current indications? | G C.Schuler ( Leipzig-Germany) | valvular disease | 30 Aug 2011 |
| Controversial issues on transcatheter aortic valve implantation | Very high-risk patients with aortic stenosis: TAVI, balloon or nothing? | J.Rodes Cabau ( Sainte-Foy-Canada) | valvular disease | 30 Aug 2011 |
| Controversial issues on transcatheter aortic valve implantation | Is valve-in-valve the preferred treatment for bioprosthesis failure? | D.Himbert ( Paris-France) | valvular disease | 30 Aug 2011 |
| Primary percutaneous coronary intervention: from evidence to practice | Controversies in antithrombotic treatment. | A.Kastrati ( Munchen-Germany) | Ischaemia / ACS / infarction | 30 Aug 2011 |
| Primary percutaneous coronary intervention: from evidence to practice | Drug-eluting or bare metal stents? | M.Valgimigli ( Ferrara-Italy) | Ischaemia / ACS / infarction | 30 Aug 2011 |
| Primary percutaneous coronary intervention: from evidence to practice | The challenge of multi-vessel disease. | C.Di Mario ( London-United Kingdom) | Ischaemia / ACS / infarction | 30 Aug 2011 |
| Primary percutaneous coronary intervention: from evidence to practice | Dealing with microvascular obstruction. | F.Crea ( Roma-Italy) | Ischaemia / ACS / infarction | 30 Aug 2011 |
| New therapies for mitral regurgitation | Surgical strategies. | M.De Bonis ( Milano-Italy) | Interventional cardiology | 30 Aug 2011 |
| New therapies for mitral regurgitation | Percutaneous edge to edge technique. | OW.Franzen ( Copenhagen-Denmark) | Interventional cardiology | 30 Aug 2011 |
| New therapies for mitral regurgitation | Percutaneous coronary sinus annuloplasty. | J.Harnek ( Lund-Sweden) | Interventional cardiology | 30 Aug 2011 |
| New therapies for mitral regurgitation | The bird's eye view. | A.Vahanian ( Paris-France) | Interventional cardiology | 30 Aug 2011 |
| Joint Guidelines for the detection and treatment of dyslipidemias | Plasma lipids and global cardiovascular risk. | I M.Graham ( Dublin-Ireland) | Pharmacology and pharmacotherapy | 30 Aug 2011 |
| Joint Guidelines for the detection and treatment of dyslipidemias | Controlled clinical trials and cardiovascular risk. | G.De Backer ( St Martens Latem-Belgium) | Pharmacology and pharmacotherapy | 30 Aug 2011 |
| Joint Guidelines for the detection and treatment of dyslipidemias | The new joint Guidelines: an overview. | M-R.Taskinen ( Helsinki-Finland) | Pharmacology and pharmacotherapy | 30 Aug 2011 |
| Joint Guidelines for the detection and treatment of dyslipidemias | New biomarkers for atherosclerosis. | O.Wiklund ( Goteborg-Sweden) | Pharmacology and pharmacotherapy | 30 Aug 2011 |
| EURObservational Research Programme of the ESC. Ongoing Registries | EORP: what and why. | L.Tavazzi ( Cotignola-Italy) | | 30 Aug 2011 |
| EURObservational Research Programme of the ESC. Ongoing Registries | General Registry: Heart Failure. | A P.Maggioni ( Florence-Italy) | heart failure / LV dysfunction | 30 Aug 2011 |
| EURObservational Research Programme of the ESC. Ongoing Registries | Sentinel Registry: Ablation in Atrial Fibrillation. | J.Brugada Terradellas ( Barcelona-Spain) | Arrhythmias / Pacing / Resynchronisation | 30 Aug 2011 |
| EURObservational Research Programme of the ESC. Ongoing Registries | Special Registry: Pregnancy in Cardiac Disease. | J W.Roos-Hesselink ( Rotterdam-Netherlands) | | 30 Aug 2011 |
| Hot Line III - Acute coronary syndromes | PRODIGY: Randomized comparison of six versus twenty-four months clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all comer patients undergoing percutaneous coronary intervention. Results of the PRODIGY trial. | M.Valgimigli ( Ferrara-Italy) | Interventional cardiology | 30 Aug 2011 |
| Hot Line III - Acute coronary syndromes | Discussant - PRODIGY: Randomized comparison of six versus twenty-four months clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all comer patients undergoing percutaneous coronary intervention. Results of the PRODIGY trial. | A.Kastrati ( Munchen-Germany) | Interventional cardiology | 30 Aug 2011 |
| Hot Line III - Acute coronary syndromes | The RUBY-1 trial: safety, tolerability and efficacy of YM150, an oral factor Xa inhibitor, in secondary prevention of ischaemic vascular events in patients following a acute coronary syndrome | P G.Steg ( Paris Cedex 18-France) | Ischaemia / ACS / infarction | 30 Aug 2011 |
| Hot Line III - Acute coronary syndromes | Discussant - The RUBY-1 trial: safety, tolerability and efficacy of YM150, an oral factor Xa inhibitor, in secondary prevention of ischaemic vascular events in patients following a acute coronary syndrome | S D.Kristensen ( Aarhus N-Denmark) | Ischaemia / ACS / infarction | 30 Aug 2011 |
| Hot Line III - Acute coronary syndromes | EXAMINATION: A randomized comparison between everolimus-eluting stent and bare metal stent in patients with ST-segment elevation myocardial infarction: the EXAMINATION trial | M.Sabate Tenas ( Barcelona-Spain) | Interventional cardiology | 30 Aug 2011 |
| Hot Line III - Acute coronary syndromes | Discussant - EXAMINATION: A randomized comparison between everolimus-eluting stent and bare metal stent in patients with ST-segment elevation myocardial infarction: the EXAMINATION trial | W.Wijns ( Aalst-Belgium) | Interventional cardiology | 30 Aug 2011 |
| Hot Line III - Acute coronary syndromes | Newer generation everolimus-eluting stents eliminate the risk of very late stent thrombosis compared with early generation sirolimus-eluting and paclitaxel-eluting stents | L.Raber ( Bern-Switzerland) | Interventional cardiology | 30 Aug 2011 |
| Hot Line III - Acute coronary syndromes | Discussant - Newer generation everolimus-eluting stents eliminate the risk of very late stent thrombosis compared with early generation sirolimus-eluting and paclitaxel-eluting stents | J.Fajadet ( Toulouse Cedex 3-France) | Interventional cardiology | 30 Aug 2011 |
| Hot Line III - Acute coronary syndromes | CRISP AMI: A multi-center, randomized, controlled study of mechanical left ventricular unloading with Counterpulsation to Reduce Infarct size pre-PCI for Acute Myocardial Infarction: rationale and design of the CRISP AMI trial | M.Patel ( Durham-United States of America) | Ischaemia / ACS / infarction | 30 Aug 2011 |
| Hot Line III - Acute coronary syndromes | Discussant - CRISP AMI: A multi-center, randomized, controlled study of mechanical left ventricular unloading with Counterpulsation to Reduce Infarct size pre-PCI for Acute Myocardial Infarction: rationale and design of the CRISP AMI trial | K.Huber ( Vienna-Austria) | Ischaemia / ACS / infarction | 30 Aug 2011 |
| EURObservational Research Programme of the ESC. Forthcoming Registries | General Registry: Chronic Ischaemic Heart Disease. | R.Ferrari ( Ferrara-Italy) | Ischaemia / ACS / infarction | 31 Aug 2011 |
| EURObservational Research Programme of the ESC. Forthcoming Registries | Sentinel Registry: Transcutaneous Valve Treatment. | C.Di Mario ( London-United Kingdom) | Interventional cardiology | 31 Aug 2011 |
| EURObservational Research Programme of the ESC. Forthcoming Registries | Special Registry: Cardiomyopathies. | P M.Elliott ( London-United Kingdom) | Myocardial-Pericardial disease | 31 Aug 2011 |
| EURObservational Research Programme of the ESC. Forthcoming Registries | Ancillary to Heart Failure Registry: Peripartum Cardiomyopathy. | K.Sliwa-Hahnle ( Cape Town-South Africa) | Myocardial-Pericardial disease | 31 Aug 2011 |
| Controversies on marathon and beyond | Elevated biomarkers as a proof of cardiac damage: Pro | GP.Whyte ( Liverpool-United Kingdom) | Sports cardiology | 31 Aug 2011 |
| Controversies on marathon and beyond | Elevated biomarkers as a proof of cardiac damage: Contra. | J.Scharhag ( Heidelberg-Germany) | Sports cardiology | 31 Aug 2011 |
| Controversies on marathon and beyond | Pre-participation screening is warranted Pro. | D.Corrado ( Padova-Italy) | Sports cardiology | 31 Aug 2011 |
| Controversies on marathon and beyond | Pre-participation screening is warranted: Contra. | S.Sharma ( London-United Kingdom) | Sports cardiology | 31 Aug 2011 |
| Controversies on marathon and beyond | Pre-participation screening is warranted: Pro. | D.Corrado ( Padova-Italy) | Sports cardiology | 31 Aug 2011 |
| Highlight Session | Hypertension. | R.Schmieder ( Erlangen-Germany) | | 31 Aug 2011 |
| Highlight Session | Imaging. | J L.Zamorano Gomez ( Madrid-Spain) | | 31 Aug 2011 |
| Highlight Session | Arrhythmias. | H.Heidbuchel ( Leuven-Belgium) | | 31 Aug 2011 |
| Highlight Session | Acute coronary syndromes. | J L.Lopez-Sendon ( Madrid-Spain) | | 31 Aug 2011 |
| Highlight Session | Interventional cardiology. | K.Huber ( Vienna-Austria) | | 31 Aug 2011 |
| Highlight Session | Valvular heart disease and pulmonary circulation. | A.Torbicki ( Warsaw-Poland) | | 31 Aug 2011 |
| Highlight Session | Heart failure and cardiomyopathies. | S D.Anker ( Berlin-Germany) | | 31 Aug 2011 |
| Highlight Session | Preventive cardiology. | D A.Wood ( London-United Kingdom) | | 31 Aug 2011 |
| Highlight Session | Basic Science | A R. Pries (Berlin-Germany) | | 31 Aug 2011 |